TheraRadar
Data updated: May 26, 2026

ALTUVIIIO (antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl)

Approved 2023-02-21
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2023-02-21
Patent Cliff
2030
Revenue
$358M (Q4-2025)

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intravenous
Dosage Forms
For Injection

Companies

Sanofi
Active Ingredient: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl , antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl

ALTUVIIIO Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2023 to 2023
Feb 2023 ORIGINAL
Update · CBER biologic (Purple Book)

What ALTUVIIIO Treats

1 FDA approvals

Originally approved for its first indication in 2023 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ALTUVIIIO FDA Label Details

Pro Intelligence Preview

Deep insights for ALTUVIIIO

Revenue Insights

  • • Q4-2025: $358M
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2030
  • • Generic/biosimilar risk

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: BLA125771 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.